Acute myeloid leukemia
Conditions
Interventions
trial group:Azacitidine Combined with Low-Dose Cytarabine regimen
Sponsors
The First Affiliated Hospital, College of Medicine, Zhejiang University
Eligibility
Sex/Gender
All
Age
65 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Diagnosed as acute myeloid leukemia by routine examinations such as bone marrow and immunophenotyping according to the 2016 World Health Organization (WHO) classification of AML. 2. Aged >= 65 years. 3. Patients are not suitable for intensive chemotherapy according to the evaluation of the researchers, and must meet >= 1 of the following criteria: (1) ECOG PS >= 3; (2) Charlson comorbidity index (CCI) > 1; (3) Activity of daily living (ADL) <= 60. 4. Patients did not receive any systemic treatment for acute myeloid leukemia before enrolling in the trial. 5. Life expectancy is more than two months. 6. Patients must sign the informed consent form before taking any test related to the trial.
Exclusion criteria
Exclusion criteria: 1. Acute promyelocytic leukemia. 2. Patients with secondary AML who prior treatment with HMAs for myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML). 3. History of malignancy other than acute myeloid leukemia in recent five years. 4. Patients with known human immunodeficiency virus (HIV) infection. 5. Pregnant or lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CR+CRi+MLFS; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall Survival;Progress-free survival; | — |
Countries
China
Contacts
Public ContactXiujin Ye
The First Affiliated Hospital, College of Medicine, Zhejiang University
Outcome results
None listed